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(J Thorac Oncol. 2007;2: Suppl 1, 47)
Stereotactic body radiation therapy (SBRT) offers a non-invasive treatment modality for patients with early-stage
(stage IA or IB) non-small cell lung cancer (NSCLC) not
amenable to surgery because of medical reasons or patient
refusal. The aim of this prospective study was to analyze
feasibility, toxicity, and response rate to an expressively
designed hypofractionated SBRT regimen.
MATERIALS AND METHODS
FromMay 2003 to December 2006, 54 patients with stage
I NSCLC were treated using SBRT at the University of Turin,
Italy. The treatment was based on the methods first described by
Lax andBlomgren fromKarolinskaHospital, Stockholm, Sweden.1
Staging work-up included computed tomography (CT)
scan, positron emission tomography (PET) scan, and pulmo-
nary function tests. Patients were immobilized in a stereotac-
tic body frame, and breathing motility was reduced mechan-
ically by means of a diaphragm control device, when
necessary. Gross tumor volume (GTV), planning target vol-
ume (PTV), and organs-at-risk were defined in accordance
with ICRU-62 on a CT data set acquired with 2.5-mm slice
thickness over the entire lung volume. The PTV included the
GTV with a standard margin of 5 mm on the axial plan and
10 mm on the longitudinal direction. All patients were treated
with three fractions of 15 Gy during 5 days. The dose was
prescribed to the 80% isodose line and delivered with six to
eight non-coplanar static multiple fields.
Dose-volume histograms (DVHs), tumor control proba-
bility, and normal tissue complication probability (LKB model)
were obtained and evaluated for each case. Early and late
toxicities were graded using the Radiation Therapy Oncology
Group Radiation Toxicity Scale (RTOG). The follow-up exam-
ination included CT scans 45 days after extracranial stereotactic
radiotherapy, every 3 months for the first 2 years, and every 6
months for another 3 years; PET/CT scan 3 months and 1 year
after ESRT; and pulmonary function tests every 3 months for the
first 2 years and every 6 months for another 3 years. Tumor
response was evaluated on CT scan using the Response Evalu-
ation Criteria in Solid Tumors (RECIST).2 Local tumor control
was defined as the absence of progressive disease.
RESULTS
Of the 54 patients, 43 were considered for analysis.
Nine patients were excluded because of limited follow-up,
and two patients were lost to follow-up within the study
period. The median follow-up time was 14.7 months (range,
3–44 months). Crude local control was 100% with 19 com-
plete response (44.2%), 14 partial response (32.5%), and 10
stable disease (23.3%). Fifteen patients with local tumor
control developed systemic disease and/or regional nodal re-
lapse. In December 2006, 36 patients were alive and seven
patients had died: four from progression disease and three from
other causes not related to neoplastic pulmonary disease.
Three patients experienced slight temporary erythema
(grade 1). Radiation pneumonitis RTOG grade 1 or more was
observed globally in 15 of 43 patients: nine grade 1, four
grade 2, and two grade 3. A concomitant infection was
diagnosed in one patients with grade 3 acute pneumonitis.
Rib fracture occurred in one patient with a very peripherical
tumor located close to the chest wall. Interestingly, some
patients developed significant thoracic pain that was difficult
to manage with drugs and was probably related to high
radiation doses received by the peripheral nerves. No other
treatment-related toxicities were observed.
CONCLUSION
Stereotactic radiotherapy for stage I NSCLC is a fea-
sible, safe, and effective procedure that allows significant
dose escalation to the tumor to achieve better control proba-
bilities than conventional radiotherapy.
A larger population and a longer follow-up period
would be useful in assessing the full clinical benefit of SBRT
in early-stage NSCLC as a valid alternative to surgery for
patients with medically or functionally unresectable tumors.
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